Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC
Clinical trial NCT04924179 · UNKNOWN
Trial details
- NCT number
- NCT04924179
- Sponsor
- Huazhong University of Science and Technology
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-01
- Primary completion
- 2022-12-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.